Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
作者信息
O'Brien Thomas R, Thomas David L, Jackson Sarah S, Prokunina-Olsson Ludmila, Donnelly Raymond P, Hartmann Rune
机构信息
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
Abstract
摘要
相似文献
1
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒2对干扰素表达的弱诱导作用支持了干扰素λ治疗早期2019冠状病毒病的临床试验。
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
2
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.SARS-CoV-2 和 SARS-CoV 在人肺中的比较复制和免疫激活特征：一项具有 COVID-19 发病机制意义的离体研究。
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
3
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.Ⅰ型和Ⅲ型干扰素限制 SARS-CoV-2 感染人呼吸道上皮细胞。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00985-20.
4
Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?固有免疫信号和蛋白水解途径在新冠病毒 2 型（SARS-CoV-2）引起的新冠肺炎（Covid-19）中的转归或恶化：关键治疗靶点？
Front Immunol. 2020 May 28;11:1229. doi: 10.3389/fimmu.2020.01229. eCollection 2020.
5
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
6
Interplay between SARS-CoV-2 and the type I interferon response.SARS-CoV-2 与 I 型干扰素应答的相互作用。
PLoS Pathog. 2020 Jul 29;16(7):e1008737. doi: 10.1371/journal.ppat.1008737. eCollection 2020 Jul.
7
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.I 型和 III 型干扰素 - 诱导、信号转导、逃逸及其在抗击 COVID-19 中的应用。
Cell Host Microbe. 2020 Jun 10;27(6):870-878. doi: 10.1016/j.chom.2020.05.008. Epub 2020 May 27.
8
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.人呼吸道和结膜中冠状病毒 SARS-CoV-2 的趋向性、复制能力和先天免疫反应：离体和在体培养分析。
Lancet Respir Med. 2020 Jul;8(7):687-695. doi: 10.1016/S2213-2600(20)30193-4. Epub 2020 May 7.
9
Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.通过对固有免疫的控制调节来预防和治疗 COVID-19 疾病。
Eur J Immunol. 2020 Jul;50(7):932-938. doi: 10.1002/eji.202048693. Epub 2020 Jun 15.
10
More questions than answers, and a way ahead.问题多于答案，以及一条前行之路。
G Ital Nefrol. 2020 Apr 9;37(2):2020-vol2.
引用本文的文献
1
Targeting CTP synthetase 1 to restore interferon induction and impede nucleotide synthesis in SARS-CoV-2 infection.靶向CTP合成酶1以恢复干扰素诱导并阻碍新冠病毒感染中的核苷酸合成。
mBio. 2025 Apr 29:e0064925. doi: 10.1128/mbio.00649-25.
2
COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes.COVID-19 和流感感染介导肺部细胞和转录组的不同变化。
Commun Biol. 2023 Dec 13;6(1):1265. doi: 10.1038/s42003-023-05626-z.
3
Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2.细菌诱导或被动给予的干扰素 γ 可使肺部适应早期控制 SARS-CoV-2。
Nat Commun. 2023 Dec 12;14(1):8229. doi: 10.1038/s41467-023-43447-0.
4
Association of Interferon Lambda 3 and 4 Gene SNPs and Their Expression with COVID-19 Disease Severity: A Cross-Sectional Study.干扰素λ3和4基因单核苷酸多态性及其表达与COVID-19疾病严重程度的关联：一项横断面研究
Infect Drug Resist. 2023 Oct 10;16:6619-6628. doi: 10.2147/IDR.S422095. eCollection 2023.
5
Viral recognition and the antiviral interferon response.病毒识别与抗病毒干扰素反应。
EMBO J. 2023 Jul 17;42(14):e112907. doi: 10.15252/embj.2022112907. Epub 2023 Jun 27.
6
IFNλ: balancing the light and dark side in pulmonary infection.IFNλ：平衡肺部感染中的明暗两面。
mBio. 2023 Aug 31;14(4):e0285022. doi: 10.1128/mbio.02850-22. Epub 2023 Jun 6.
7
Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV.巨细胞病毒血清阳性老年人中干扰素-λ-3多态性对COVID-19抗体反应的评估。
Vaccines (Basel). 2023 Feb 18;11(2):480. doi: 10.3390/vaccines11020480.
8
Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study.新型冠状病毒肺炎患者的中和单克隆抗体：一项观察性研究。
Virol J. 2022 Dec 15;19(1):218. doi: 10.1186/s12985-022-01944-6.
9
Phase separation in immune regulation and immune-related diseases.免疫调节和免疫相关疾病中的相分离。
J Mol Med (Berl). 2022 Oct;100(10):1427-1440. doi: 10.1007/s00109-022-02253-9. Epub 2022 Sep 9.
10
Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries.通过基因组规模的自组装 DNA 编码蛋白文库无偏发现与严重 COVID-19 相关的自身抗体。
Nat Biomed Eng. 2022 Aug;6(8):992-1003. doi: 10.1038/s41551-022-00925-y. Epub 2022 Aug 19.
本文引用的文献
1
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.SARS-CoV-2 和 SARS-CoV 在人肺中的比较复制和免疫激活特征：一项具有 COVID-19 发病机制意义的离体研究。
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
2
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
3
HBV/HDV Coinfection: A Challenge for Therapeutics.HBV/HDV 合并感染：治疗的挑战。
Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24.
4
Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis.当前中东呼吸综合征医疗方法的临床疗效：系统评价和荟萃分析。
Rev Med Virol. 2018 May;28(3):e1977. doi: 10.1002/rmv.1977. Epub 2018 Apr 17.
5
IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission.IFN-λ 可阻止流感病毒从上呼吸道传播到肺部，并限制病毒传播。
Elife. 2018 Apr 13;7:e33354. doi: 10.7554/eLife.33354.
6
Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness.干扰素-λ 通过非冗余的一线抗病毒保护作用来抵抗流感病毒感染，而不损害宿主的适应性。
Immunity. 2017 May 16;46(5):875-890.e6. doi: 10.1016/j.immuni.2017.04.025.
7
IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.IFNλ是一种有效的抗流感治疗药物，没有IFNα治疗的炎症副作用。
EMBO Mol Med. 2016 Sep 1;8(9):1099-112. doi: 10.15252/emmm.201606413. Print 2016 Sep.
8
SARS and MERS: recent insights into emerging coronaviruses.严重急性呼吸综合征和中东呼吸综合征：对新型冠状病毒的最新见解
Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27.
9
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.一项聚乙二醇干扰素 lambda-1a 治疗慢性 HCV 感染的随机 2b 期研究。
J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.
10
Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia.I型和III型干扰素驱动冗余放大环，以在流感感染的气道上皮细胞中诱导转录特征。
PLoS Pathog. 2013;9(11):e1003773. doi: 10.1371/journal.ppat.1003773. Epub 2013 Nov 21.
Zotero 插件